Patients with skin conditions are three times more likely to experience pruritus, highlighting a critical link between dermatologic health and quality of life.
New data from three Phase 3 trials show upadacitinib maintains strong efficacy and safety in adolescent atopic dermatitis, with significant improvements in pruritus and skin clearance.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A recent study suggests that proactive monitoring of infliximab during maintenance therapy may increase sustained disease control in patients with inflammatory bowel disease and arthritis, potentially adding 146 more patients per 1,000 to annual remission rates.
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.